NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference.
Follow this link:
Mesoblast Corporate Presentation at Investor Conference
SYDNEY, AUSTRALIA, June 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), through a subsidiary, to evaluate eftilagimod alfa (efti) in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in a pivotal Phase III trial.
See the rest here:
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).
Go here to read the rest:
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
Allschwil, Switzerland – June 3, 2024
Originally posted here:
New data with daridorexant to be presented at SLEEP 2024
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan
Link:
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) protecting a group of molecules and their ability to trigger an immune response across a wide range of cancers by detaching the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores. The molecules are the crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275.
Nicox SA Société anonyme with a registered capital of € 502,996.94
Read the original:
Number of voting rights as of May 31, 2024
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June:
Read more here:
Pharming Group to participate in June investor conferences
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves
Go here to read the rest:
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care